{"id":"bcd-063","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCD-063 targets interleukin-17A (IL-17A), a key cytokine in the IL-17 signaling pathway that drives inflammation in autoimmune conditions. By neutralizing IL-17A, the drug reduces inflammatory responses and immune cell activation. This mechanism is particularly relevant for conditions characterized by Th17-mediated inflammation, such as psoriasis and other autoimmune disorders.","oneSentence":"BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:46.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT02753088","phase":"PHASE3","title":"Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glatiramer acetate"],"phase":"phase_3","status":"active","brandName":"BCD-063","genericName":"BCD-063","companyName":"Biocad","companyId":"biocad","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. Used for Psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}